West Virginia MPJE (Pharmacy Jurisprudence) Practice Exam

The correct answer is that the collaborating physician must co-sign the detailed statement of what the pharmacist did under a Collaborative Practice Agreement (CPA) within one week of a drug management change. In the context of CPAs, pharmacists have the authority to manage medications, but they operate under a structured agreement that typically includes a collaborating physician's oversight. This requirement ensures accountability and adherence to the agreed-upon treatment plans while allowing for collaborative care between the pharmacist and physician.

The need for the collaborating physician’s co-signature reflects the importance of communication and coordinated care in patient management, particularly when medication adjustments are made. The collaborating physician is essential for ensuring that the pharmacist's interventions are in alignment with the overall treatment goals for the patient.

Other roles, such as the patient's caregiver, pharmacist-in-charge, or patient's nurse, do not hold the same regulatory requirement for co-signing in this specific context of drug management changes under a CPA. Their involvement may vary depending on care coordination but does not equate to the formal oversight provided by the collaborating physician in this setting.